
    
      All patients will receive FOLFOX/bevacizumab for four 28-day cycles (a total of 16 weeks).
      After 4 cycles, maintenance axitinib will be started. With approval of the Medical
      Monitor,patients who are having significant benefit from FOLFOX/bevacizumab may continue
      chemotherapy to a maximum of six 28-day cycles. During trial treatment, all patients will be
      assessed for response every 8 weeks (2 cycles).
    
  